Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A phase 3 trial of HLP003 (deuterated psilocin) as an add-on therapy for major depressive disorder (MDD) hit its primary and secondary endpoints with impressive results. Patients on HLP003 saw nearly double the symptom reduction compared to placebo by week 6, with benefits appearing as early as day 2. Helus Pharma says the results could redefine what's possible for patients still struggling despite being on antidepressants.
Helus Pharma has announced positive topline results from its phase 3 APPROACH study, evaluating HLP003 — a deuterated form of psilocin — as an adjunctive treatment for major depressive disorder (MDD). The trial enrolled 222 adults with moderate-to-severe MDD who continued their existing antidepressant regimens throughout the study, making HLP003 an add-on rather than a replacement therapy.
The results were notable: patients on HLP003 showed nearly double the symptom reduction on the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo at both the 6-week primary endpoint and the 12-week secondary endpoint. Meaningful improvements were already visible just two days after treatment began, suggesting a rapid onset of action — a key advantage over many conventional antidepressants.
By the Numbers:
Why it matters: Millions of MDD patients continue to experience persistent symptoms despite being on antidepressants. A fast-acting, well-tolerated adjunctive option like HLP003 could fill a critical gap in psychiatric care, offering new hope for those who haven't responded adequately to existing treatments.